Editor’s note: Comstock’s welcomes opinion pieces from a variety of perspectives. To submit a piece for consideration, please email Digital Editor Jennifer Fergesen at jfergesen@comstocksmag.com.

The reality is far messier. 

The vast majority of genuinely important scientific innovations never make it past the lab. They sit in journals, get cited by other researchers, and eventually fade. The science is often right. What is missing is a repeatable model for crossing the distance between a working discovery and a commercial enterprise.

Academics are trained to lead with the solution and convince others the problem is worth caring about because that is how grant funding works. Commercial markets operate differently. Customers already understand the problems they face.They want solutions that fit naturally into their workflows, behaviors, and budgets. Finding genuine product-market fit, starting from market need rather than technological capability, is a discipline many scientific founders have never had to learn.

What the bridge should actually look like

A few years ago, I began working with researchers exploring a new enzymatic approach to caffeine reduction in coffee. This work emerged from relationships built within the UC Davis innovation ecosystem, where researchers, investors, entrepreneurs, and industry partners increasingly collaborate to move promising science beyond the lab. 

Early market analysis revealed a growing consumer interest in moderating caffeine intake while still preserving the experience and ritual of coffee itself. What began as an academic research concept eventually evolved into a venture-backed company developing caffeine-control technology and engaging with some of the largest players in the global coffee industry.

What mattered most in that process was not simply the underlying science. It was the ability to connect scientific discovery to market demand, assemble talent and the operational infrastructure required to commercialize the technology, and support the transition from research project to scalable business.

Related: A Quarter Century of Startups: Big Bang! Finalists Share $100K in Milestone Year

That experience reinforced something I have seen repeatedly over the past decade: scientific discovery and company creation are entirely different disciplines.

Universities like UC Davis are uniquely positioned to help close this gap because they combine world-class research talent with growing commercialization infrastructure and industry collaboration. The challenge is that scientific discovery alone is rarely enough to create enduring companies. The surrounding operational ecosystem matters just as much.

Building a bridge between science and real-world change begins long before a company legally exists. It means committing capital while technology is still inside a university lab and evaluating whether a scientific breakthrough can survive in a commercial environment. It requires understanding the science deeply enough to distinguish meaningful innovation from technically interesting ideas with limited real-world application, while also pressure-testing the commercial case before institutional funding arrives.

Related: Women-Led Startups Are Growing — So Why Is VC Funding Still So Low?

In practice, this work becomes highly operational. Investors operating in this space often help shape go-to-market strategy, recruit leadership, structure licensing agreements, support fundraising, assemble domain expertise, and build the organizational systems required for long-term execution. The role extends far beyond capital allocation. It requires thinking and operating like a founder.

That can also mean stepping directly into operational leadership when necessary. I spent eighteen months serving as CEO of one portfolio company before we hired the right long-term leader for the role. During that period, I helped assemble domain experts, negotiate licensing agreements, lead customer discovery, shape commercialization strategy, raise initial capital, and develop the operational infrastructure the company would ultimately need.

Related: Female Startup Founders Share the Decisions That Changed Everything

The human side of the transition matters just as much. A world-class scientist may have little experience designing a scalable supply chain, navigating regulatory pathways, negotiating manufacturing partnerships, or assembling the operational leadership required to scale a business.

Some scientist-founders thrive inside venture-backed startups and become exceptional operators. Others create the greatest value through research leadership while partnering with experienced entrepreneurs who can guide commercialization and growth. Understanding those dynamics early is one of the most important parts of company creation because the strongest outcomes emerge when scientific expertise is preserved and reinforced with complementary operational capabilities.

Related: Standout Startups: How Did These Capital Region Entrepreneurs Succeed Where So Many Have Fallen Short?

This work also requires patience. Biotechnology, food science, health innovation, energy, and advanced materials all operate on timelines that differ significantly from software or AI technology. Scientific validation, regulatory review, manufacturing scale-up, and customer adoption often unfold over years rather than quarters. Investors working in these sectors need the ability to support companies through long development cycles without forcing decisions the science is not yet ready to support.

None of this happens from a distance, and it cannot be done at scale across dozens of companies simultaneously. It requires operational depth, sustained involvement, and a willingness to spend years helping build the foundations of a company before the market fully recognizes the opportunity.

One lesson I learned early is that successful commercialization depends heavily on trust-based ecosystems connecting researchers, operators, universities, and investors. Strong scientific ecosystems create environments where discoveries can move more efficiently from research into real-world application because they reduce friction between invention, tech transfer, and execution. They also create repeatable pathways for venture creation instead of forcing every company to reinvent the process from scratch.

Over nearly a decade of building companies from university labs, a few principles have consistently shaped successful outcomes

Universities continue to produce extraordinary breakthroughs across food, health, biotechnology, energy, and materials science. What remains underdeveloped is the infrastructure layer capable of helping those discoveries navigate a path toward commercialization.

Related: Startups of the Month: Where Are They Now?

Some universities are beginning to build far stronger ecosystems around translational innovation. At UC Davis, for example, the Innovation Institute for Food and Health has helped foster closer collaboration between researchers, operators, investors, and industry partners working across food, health, and biotechnology. That kind of ecosystem matters because scientific commercialization rarely succeeds in isolation. The strongest innovation environments create repeatable pathways for translating research into companies by combining scientific talent with commercialization support, operational expertise, and long-term industry collaboration.

This is the real work of transforming university research into companies capable of creating lasting real-world impact. 

Aryeh Ganz is an advisory board member of the UC Davis Innovation Institute for Food and Health (IIFH) and managing partner of Cornucopian Capital.

–

Stay up to date on business in the Capital Region: Subscribe to the Comstock’s newsletter today.